Myriad Genetics outlines expanded cancer care focus and launches new MyRisk panel to drive 2026 growth

5 hours ago 1

Earnings Call Insights: Myriad Genetics (MYGN) Q3 2025

Management View

Samraat Raha, President and CEO, reported revenue of $206 million, noting a 4% year-over-year decrease but emphasized that, excluding prior headwinds such as UnitedHealthcare’s GeneSight decision and the EndoPredict divestiture, the business was stable compared to Q3

Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed.

Please see full earnings call transcripts

here.

The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

Read Entire Article